Archives of Pharmacal Research

, Volume 35, Issue 7, pp 1279–1286

Attenuation of scopolamine-induced cognitive dysfunction by obovatol

Authors

  • Dong-Young Choi
    • College of PharmacyChungbuk National University
    • Medical Research CenterChungbuk National University
  • Young-Jung Lee
    • College of PharmacyChungbuk National University
    • Medical Research CenterChungbuk National University
    • CBITRCChungbuk National University
  • Sun Young Lee
    • College of PharmacyChungbuk National University
    • Medical Research CenterChungbuk National University
    • CBITRCChungbuk National University
  • Yoot Mo Lee
    • College of PharmacyChungbuk National University
    • CBITRCChungbuk National University
  • Hyun Hee Lee
    • College of PharmacyChungbuk National University
    • Medical Research CenterChungbuk National University
    • CBITRCChungbuk National University
  • Im Seop Choi
    • College of PharmacyChungbuk National University
    • CBITRCChungbuk National University
  • Ki-Wan Oh
    • College of PharmacyChungbuk National University
  • Sang Bae Han
    • College of PharmacyChungbuk National University
    • Medical Research CenterChungbuk National University
    • CBITRCChungbuk National University
  • Sang-Yoon Nam
    • College of Veterinary Medicine and Research Institute of Veterinary Medicine, Core Research InstituteChungbuk National University
    • College of PharmacyChungbuk National University
    • Medical Research CenterChungbuk National University
    • CBITRCChungbuk National University
    • College of PharmacyChungbuk National University
Research Articles Drug Actions

DOI: 10.1007/s12272-012-0719-1

Cite this article as:
Choi, D., Lee, Y., Lee, S.Y. et al. Arch. Pharm. Res. (2012) 35: 1279. doi:10.1007/s12272-012-0719-1

Abstract

Alzheimer’s disease (AD) is the most prevalent cause of dementia in the elderly people. The disease is pathologically characterized by extracellular deposition of beta-amyloid peptide (Aβ), cholinergic neurodegeneration and elevation of acetylcholine esterase (AChE) activity in the affected regions. In this study, we investigated the effects of obovatol on memory dysfunction, which was caused by scopolamine. Obovatol (0.2, 0.5 and 1 mg/kg for 7 day) attenuated scopolamine (1 mg/kg, i.p.)-induced amnesia in a dose-dependent manner, as revealed by the Morris water maze test and step-through passive avoidance test. Mechanism studies exhibited that obovatol dose-dependently alleviated scopolamine-induced increase in Aβ generation and β-secretase activity in the cortex and hippocampus. Obovatol also attenuated scopolamine-induced rise in AChE activity in the cortex and hippocampus. Obovatol might rescue scopolamine-mediated impaired learning and memory function by attenuating Aβ accumulation and stabilizing cholinergic neurotransmission, which suggests that the natural compound could be a useful agent for the prevention of the development or progression of AD neurodegeneration.

Key words

Alzheimer’s diseaseMemoryObovatolScopolamineSecretaseAcetylcholine esterase
Download to read the full article text

Copyright information

© The Pharmaceutical Society of Korea and Springer Netherlands 2012